+

WO2007049098A3 - Therapeutic formulations for the treatment of beta-amyloid related diseases - Google Patents

Therapeutic formulations for the treatment of beta-amyloid related diseases Download PDF

Info

Publication number
WO2007049098A3
WO2007049098A3 PCT/IB2005/004199 IB2005004199W WO2007049098A3 WO 2007049098 A3 WO2007049098 A3 WO 2007049098A3 IB 2005004199 W IB2005004199 W IB 2005004199W WO 2007049098 A3 WO2007049098 A3 WO 2007049098A3
Authority
WO
WIPO (PCT)
Prior art keywords
related diseases
agent
treatment
beta
therapeutic formulations
Prior art date
Application number
PCT/IB2005/004199
Other languages
French (fr)
Other versions
WO2007049098A2 (en
Inventor
Francine Gervais
Francesco Bellini
Original Assignee
Neurochem Int Ltd
Francine Gervais
Francesco Bellini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/871,549 external-priority patent/US20050142191A1/en
Priority claimed from US10/871,543 external-priority patent/US7253306B2/en
Priority claimed from US10/871,537 external-priority patent/US20050031651A1/en
Priority claimed from US10/871,514 external-priority patent/US7414076B2/en
Priority claimed from US10/871,512 external-priority patent/US20050038000A1/en
Priority claimed from US10/871,365 external-priority patent/US7244764B2/en
Application filed by Neurochem Int Ltd, Francine Gervais, Francesco Bellini filed Critical Neurochem Int Ltd
Priority to CA002582385A priority Critical patent/CA2582385A1/en
Priority to JP2007542367A priority patent/JP2008504372A/en
Priority to EP05858504A priority patent/EP1841460A2/en
Publication of WO2007049098A2 publication Critical patent/WO2007049098A2/en
Publication of WO2007049098A3 publication Critical patent/WO2007049098A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

This invention relates to methods and pharmaceutical compositions for treating amyloid-β related diseases, including Alzheimer’s disease. The invention, for example, includes a method of concomitant therapeutic treatment of a subject, comprising administering an effective amount of a first agent and a second agent, wherein said first agent treats an amyloid-β disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement.
PCT/IB2005/004199 2004-06-18 2005-06-17 Therapeutic formulations for the treatment of beta-amyloid related diseases WO2007049098A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002582385A CA2582385A1 (en) 2004-06-18 2005-06-17 Therapeutic formulations for the treatment of beta-amyloid related diseases
JP2007542367A JP2008504372A (en) 2004-06-18 2005-06-17 Therapeutic formulations for the treatment of β-amyloid related diseases
EP05858504A EP1841460A2 (en) 2004-06-18 2005-06-17 Therapeutic formulations for the treatment of beta-amyloid related diseases

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US87161304A 2004-06-18 2004-06-18
US10/871,512 2004-06-18
US10/871,549 US20050142191A1 (en) 2003-06-23 2004-06-18 Pharmaceutical formulations of amyloid inhibiting compounds
US10/871,543 US7253306B2 (en) 2003-06-23 2004-06-18 Pharmaceutical drug candidates and methods for preparation thereof
US10/871,549 2004-06-18
US10/871,613 2004-06-18
US10/871,537 US20050031651A1 (en) 2002-12-24 2004-06-18 Therapeutic formulations for the treatment of beta-amyloid related diseases
US10/871,543 2004-06-18
US10/871,365 2004-06-18
US10/871,514 US7414076B2 (en) 2003-06-23 2004-06-18 Methods and compositions for treating amyloid-related diseases
US10/871,537 2004-06-18
US10/871,512 US20050038000A1 (en) 2003-06-23 2004-06-18 Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases
US10/871,365 US7244764B2 (en) 2003-06-23 2004-06-18 Methods and compositions for treating amyloid-related diseases
US10/871,514 2004-06-18

Publications (2)

Publication Number Publication Date
WO2007049098A2 WO2007049098A2 (en) 2007-05-03
WO2007049098A3 true WO2007049098A3 (en) 2007-10-04

Family

ID=37968188

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/004199 WO2007049098A2 (en) 2004-06-18 2005-06-17 Therapeutic formulations for the treatment of beta-amyloid related diseases

Country Status (4)

Country Link
EP (1) EP1841460A2 (en)
JP (1) JP2008504372A (en)
CA (1) CA2582385A1 (en)
WO (1) WO2007049098A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499480B2 (en) 2006-10-12 2016-11-22 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012505162A (en) * 2008-10-09 2012-03-01 ワラタ ファーマシューティカルズ， インコーポレイテッド Use of scyllo-inositol for treating macular degeneration related disorders
KR20110082590A (en) * 2008-11-14 2011-07-19 벨루스 헬스 인크. Organic Nutrients, Methods and Uses
WO2010096925A1 (en) * 2009-02-26 2010-09-02 Bellus Health (International) Limited Homotaurine-supplemented and/or enriched edible material, methods of preparation an d uses
DK3061821T3 (en) 2009-07-22 2019-08-26 PureTech Health LLC COMPOSITIONS FOR TREATMENT OF DISORDERS LINED BY MUSCARINE RECEPTOR ACTIVATION
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
US10052299B2 (en) 2009-10-30 2018-08-21 Retrotope, Inc. Alleviating oxidative stress disorders with PUFA derivatives
JP6145087B2 (en) 2011-04-26 2017-06-07 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． Disorders involving PUFA oxidation
US10154983B2 (en) * 2011-04-26 2018-12-18 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating PUFAs
KR102110200B1 (en) 2011-04-26 2020-05-13 레트로토프 인코포레이티드 Oxidative retinal diseases
AU2012249918B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Impaired energy processing disorders and mitochondrial deficiency
RU2488388C1 (en) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Pharmaceutical composition for preventing and treating mental, behaviour and cognitive disorders
CN102793694B (en) * 2012-08-14 2014-06-04 武汉华纳联合药业有限公司 Application of 3-amino-1-propanesulfonic acid and its derivative in medicine preparation for treating cerebral stroke
KR102643910B1 (en) 2015-11-23 2024-03-06 레트로토프 인코포레이티드 Site-specific isotope labeling method for 1,4-diene system
ITUA20161679A1 (en) * 2016-03-15 2017-09-15 Neuraxpharm Italy S P A COMPOSITION TO PREVENT AND TREAT NEURODEGENERATIVE PATHOLOGIES AND COGNITIVE DISORDERS
KR102080023B1 (en) 2018-01-29 2020-02-21 주식회사 종근당 Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate
KR102006777B1 (en) 2018-01-29 2019-10-08 주식회사 종근당 Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate
TWI827583B (en) 2018-03-08 2024-01-01 美商英塞特公司 AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-γ INHIBITORS
CN112367970A (en) * 2018-04-12 2021-02-12 J·大卫格莱斯顿研究所-根据J·大卫格莱斯顿遗嘱的遗嘱信托 Methods for treating APOE 4/4-related disorders
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020040438A1 (en) 2018-08-23 2020-02-27 주식회사 종근당 Pharmaceutical preparation having excellent dissolution properties, containing esomeprazole and sodium bicarbonate
CR20210212A (en) 2018-09-28 2021-09-24 Karuna Therapeutics Inc Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
US20220022881A1 (en) * 2018-12-04 2022-01-27 The Brain Protection Company PTY LTD Combinatorial therapies including implantable damping devices and therapeutic agents for treating a condition and associated systems and methods of use
WO2021168311A1 (en) 2020-02-21 2021-08-26 Retrotope, Inc. Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof
US20210353566A1 (en) * 2020-05-12 2021-11-18 Massachusetts Institute Of Technology The use of choline supplementation as therapy for apoe4-related disorders
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085093A2 (en) * 1999-12-23 2001-11-15 Neurochem, Inc. Compounds and methods for modulating cerebral amyloid angiopathy
WO2004058239A1 (en) * 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085093A2 (en) * 1999-12-23 2001-11-15 Neurochem, Inc. Compounds and methods for modulating cerebral amyloid angiopathy
WO2004058239A1 (en) * 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KISILEVSKY R ET AL: "ARRESTING AMYLOIDOSIS IN VIVO USING SMALL-MOLECULE ANIONIC SULPHONATES OR SULPHATES: IMPLICATIONS FOR ALZHEIMER'S DISEASE", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 1, no. 2, 1 February 1995 (1995-02-01), pages 143 - 148, XP000611547, ISSN: 1078-8956 *
MCGEER EDITH G ET AL: "Clinically tested drugs for Alzheimer's disease.", EXPERT OPINION ON INVESTIGATIONAL DRUGS JUL 2003, vol. 12, no. 7, July 2003 (2003-07-01), pages 1143 - 1151, XP002442171, ISSN: 1354-3784 *
ROCCA PAOLA ET AL: "Donepezil in the treatment of Alzheimer's disease: long-term efficacy and safety.", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY FEB 2002, vol. 26, no. 2, February 2002 (2002-02-01), pages 369 - 373, XP002442170, ISSN: 0278-5846 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499480B2 (en) 2006-10-12 2016-11-22 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Also Published As

Publication number Publication date
JP2008504372A (en) 2008-02-14
EP1841460A2 (en) 2007-10-10
WO2007049098A2 (en) 2007-05-03
CA2582385A1 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
WO2007049098A3 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
MXPA05006940A (en) Therapeutic formulations for the treatment of beta-amyloid related diseases.
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
WO2006035434A3 (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
MY124853A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives.
GB0211649D0 (en) Organic compounds
WO2004028570A3 (en) A method for treating severe tinnitus
WO2005005414A3 (en) Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
MY143795A (en) Tetrahydropyridoindole derivatives
WO2006083780A3 (en) Glucuronidated nebivolol
WO2007121088A3 (en) Combinations of therapeutic agents for treating cancer
WO2006130679A3 (en) Composition and method for the treatment of allergic rhinitis
WO2006073786A3 (en) Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
BRPI0413438A (en) active pyrimidylpyrrole derivatives as kinase inhibitors
WO2008105507A1 (en) Therapeutic agent for spinal cord injury
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
AU2001266289A1 (en) 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
WO2002014343A8 (en) Bufadienolide derivatives and use as immunosuppressive, antiinflammatory and analgesic agents
AU2002357191A1 (en) Derivatives of isoindigo, indigo and indirubin and use in treating cancer
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
WO2005094899A8 (en) Clusterin antisense therapy for treatment of cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2007542367

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005858504

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2582385

Country of ref document: CA

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005858504

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载